Evoke Pharma announces USPTO issued patent for GIMOTI

Evoke Pharma announced that the United States Patent and Trademark Office, USPTO, issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI. This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others. Evoke continues to see significant commercial value, particularly with the rising popularity of GLP-1 agonist medications for diabetes which are potentially unmasking gastroparesis in larger groups of patients. GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis. The ability to take the medication non-orally is important as gastroparesis causes tablets to be unpredictably absorbed. Pills may linger in the stomach instead of being passed into the intestines for absorption or not absorbed at all due to one of the key symptoms of the disease, vomiting.